½ÃÀ庸°í¼­
»óǰÄÚµå
1619040

¼¼°èÀÇ ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå - ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, ¹æ¹ýº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2024-2031³â)

Viral Clearance Market Size, Share, Growth Analysis, By Type, By Application, By End User, By Method, By Region - Industry Forecast 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 260 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ¼¼°è ½ÃÀå ±Ô¸ð´Â 2022³â¿¡ 4,929¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2023³â 5,722¾ï 6,000¸¸ ´Þ·¯¿¡¼­ 2031³â¿¡´Â 1Á¶ 8,890¾ï 7,000¸¸ ´Þ·¯·Î ¼ºÀåÇØ ¿¹Ãø±â°£(2024-2031³â) CAGRÀº 16.1%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀåÀº ´ÜŬ·ÐÇ×ü, ÀçÁ¶ÇÕ ´Ü¹éÁú, ´ç´Ü¹éÁú ¹× ±âŸ »ý¹°ÇÐÀû Á¦Á¦¸¦ Á¦Á¶ÇÒ ¶§ ¹ÙÀÌ·¯½º ÀÔÀÚ ¹× TSE º´¿øÃ¼¸¦ Á¦°ÅÇÒ Çʿ䰡 ÇʼöÀûÀ̱⠶§¹®¿¡ °ßÀηÂÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù. ÀÌ Á¦Ç°Àº ¹ÙÀÌ·¯½º, ¹ÚÅ׸®¾Æ ¹× °õÆÎÀ̸¦ ºñ·ÔÇÑ ´Ù¾çÇÑ ¿À¿° ¹°Áú·Î ÀÎÇÑ À§Çè¿¡ Á÷¸é ÇØ Àֱ⠶§¹®¿¡ °­·ÂÇÑ ¹ÙÀÌ·¯½º ¾ÈÀü Á¶Ä¡°¡ ÇʼöÀûÀÔ´Ï´Ù. ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¦¾à ¹× »ý¸í °øÇÐ ºÐ¾ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ´Ù´Â °ÍµµÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ÇÁ·Î¼¼½ºÀÇ Àü¹ÝÀûÀÎ »óȲÀº ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ºÀÇ ÄÄÇöóÀÌ¾ð½º¿Í È¿´É¿¡ Áß¿äÇÑ ÃÊÁ¡À» °­Á¶Çϸ鼭 ÇâÈÄ ¸î ³âµ¿¾È Å©°Ô ÁøÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

¼Ò°³

  • Á¶»çÀÇ ¸ñÀû
  • Á¶»ç ¹üÀ§
  • Á¤ÀÇ

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷ µ¥ÀÌÅÍ¿Í 1Â÷ µ¥ÀÌÅÍÀÇ ¹æ¹ý
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀåÀÇ ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ

ÁÖ¿ä ¿ä¾à

  • ¼¼°è ½ÃÀå Àü¸Á
  • °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¾ïÁ¦¿äÀΰú °úÁ¦
  • Porter's Five Forces ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • Á߿伺°ø¿äÀÎ
  • °æÀïµµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå »ýŰè
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2023³â)
  • PESTEL ºÐ¼®
  • °Å½Ã°æÁ¦ÁöÇ¥
  • ¹ë·ùüÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±â¼úÀÇ Áøº¸

¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå ±Ô¸ð : ¹æ¹ýº° & CAGR(2024-2031³â)

  • ½ÃÀå °³¿ä
  • ¹ÙÀÌ·¯½º Á¦°Å ¹æ¹ý
    • Å©·Î¸¶Åä±×·¡ÇÇ
    • ¿©°ú
    • °­¼ö·®
  • ¹ÙÀÌ·¯½º ºÒȰȭ¹ý
    • Ph º¯°æ
    • ¿ëÁ¦ ¼¼Á¦(S/D)
    • »ì±Õ
    • °Ç¿­
    • ±âŸ
  • ¹ÙÀÌ·¯½º °ËÃâ ¹æ¹ý
    • Â÷¼¼´ë ½ÃÄö½Ì(NGS)
    • ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR)
    • »ýü³» ºÐ¼®
    • ½ÃÇè°ü³» ºÐ¼®

¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå ±Ô¸ð : ¿ëµµº° & CAGR(2024-2031³â)

  • ½ÃÀå °³¿ä
  • Ç÷¾× ¹× Ç÷¾× Á¦Á¦
  • ÀçÁ¶ÇÕ ´Ü¹éÁú
  • ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á Á¦Ç°
  • ¹é½Å

¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå ±Ô¸ð : ÃÖÁ¾ »ç¿ëÀÚº° & CAGR(2024-2031³â)

  • ½ÃÀå °³¿ä
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¾÷°è
  • Çмú¿¬±¸±â°ü
  • CRO

¹ÙÀÌ·¯½º Ŭ¸®¾î·±½º ½ÃÀå ±Ô¸ð : Áö¿ªº° & CAGR(2024-2031³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï Á¤º¸

  • »óÀ§ 5°³»ç ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2023³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤¿ëÇÑ Àü·«
  • ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • ±â¾÷ °³¿ä
    • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
    • ºÎ¹®º° Á¡À¯À² ºÐ¼®
    • ¼öÀÍÀÇ Àü³â´ëºñ ºñ±³(2021-2023³â)

ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Charles River Laboratories
  • Merck KGaA
  • Texcell
  • WuXi AppTec
  • Sartorius AG
  • Eurofins Scientific
  • Vironova
  • Syngene International
  • Microbac Laboratories
  • Creative Biolabs
  • Nelson Labs
  • SGS AG
  • Lonza Group
  • Bioscience Laboratories
  • Labor Dr. Merk & Kollegen
  • Gilead Sciences
  • Poolbeg Pharma
  • Incyte
  • Genmab
  • Biogen

°á·Ð°ú ±ÇÀå»çÇ×

JHS 25.01.06

Global Viral Clearance Market size was valued at USD 492.9 billion in 2022 and is poised to grow from USD 572.26 billion in 2023 to USD 1889.07 billion by 2031, growing at a CAGR of 16.1% during the forecast period (2024-2031).

The viral clearance market is gaining traction due to the essential need for eliminating viral particles and TSE agents during the production of monoclonal antibodies, recombinant proteins, glycoproteins, and other biologics. As these products face risks from various contaminants, including viruses, bacteria, and fungi, robust viral safety practices are becoming imperative. Furthermore, the increasing investments in the pharmaceutical and biotechnology sectors, alongside a rising demand for vaccines and biotherapeutic agents, are propelling growth in this market. As manufacturers prioritize viral clearance to ensure product integrity and safety, the overall landscape of viral clearance processes is expected to evolve significantly in the coming years, highlighting the critical focus on compliance and efficacy in bioprocessing.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Viral Clearance market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Viral Clearance Market Segmental Analysis

Global Viral Clearance Market is segmented by method, application, end-user and region. Based on method, the market is segmented into viral removal method, viral inactivation method and viral detection method. Based on application, the market is segmented into blood and blood products, recombinant proteins, cellular & gene therapy products and vaccines. Based on end-user, the market is segmented into pharmaceutical and biotech industry, academic research institutes and cros. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Viral Clearance Market

The global viral clearance market is primarily driven by the increasing demand for biologics and vaccines, which significantly enhances market growth. Regulatory agencies place a high priority on ensuring viral safety, requiring comprehensive assessments and high-quality data for Investigational New Drug (IND) and Biologics License Application (BLA) approvals. This necessitates expertise in relevant processes and regulatory compliance, which not only facilitates strategic planning but also leads to potential savings in time, resources, and finances. Moreover, the rising prevalence of chronic viral infections and the urgent need for effective treatment options, coupled with increased investments in the life sciences sector and the development of innovative therapies, further fuel market expansion.

Restraints in the Global Viral Clearance Market

The Global Viral Clearance market faces several restraints that hinder its growth, notably the significant expenses and a shortage of skilled professionals in the field. The advanced technologies required for viral clearance studies come with high costs, which can deter investment and development. Additionally, the overall operational and procedural expenses related to viral safety add to these financial burdens, further constraining the market. The increasing demand for expertise combined with this skill gap only exacerbates these challenges, leading to higher costs and ultimately limiting the market's potential for growth and expansion in the evolving landscape of viral safety solutions.

Market Trends of the Global Viral Clearance Market

The Global Viral Clearance market is experiencing significant growth driven by an escalating demand for generics and biosimilars. As healthcare systems globally strive for cost-effective treatment options for chronic diseases, there is heightened investment in recombinant non-glycosylated proteins, which serve as a cornerstone for developing biosimilars. This trend is fueled by advancements in technology that enhance viral clearance processes, ensuring safety and efficacy. Furthermore, regulatory pressures and the increasing prevalence of chronic health conditions propel the market forward, making efficient viral clearance methodologies crucial for pharmaceutical and biopharmaceutical companies. Overall, these dynamics are shaping a robust and evolving landscape in the viral clearance sector.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2023
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technological Advancement

Global Viral Clearance Market Size by Method & CAGR (2024-2031)

  • Market Overview
  • Viral Removal Method
    • Chromatography
    • Filtration
    • Precipitation
  • Viral Inactivation Method
    • Ph Modification
    • Solvent Detergent (S/D)
    • Pasteurization
    • Dry Heat
    • Others
  • Viral Detection Method
    • Next Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • In Vivo Assay
    • In Vitro Assay

Global Viral Clearance Market Size by Application & CAGR (2024-2031)

  • Market Overview
  • Blood and Blood Products
  • Recombinant Proteins
  • Cellular & Gene Therapy Products
  • Vaccines

Global Viral Clearance Market Size by End-User & CAGR (2024-2031)

  • Market Overview
  • Pharmaceutical and Biotech Industry
  • Academic Research Institutes
  • CROs

Global Viral Clearance Market Size & CAGR (2024-2031)

  • North America (Method, Application, End-User)
    • USA
    • Canada
  • Europe (Method, Application, End-User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Method, Application, End-User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Method, Application, End-User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Method, Application, End-User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2023
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

  • Charles River Laboratories
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Texcell
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • WuXi AppTec
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sartorius AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eurofins Scientific
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vironova
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Syngene International
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Microbac Laboratories
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Creative Biolabs
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nelson Labs
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SGS AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lonza Group
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bioscience Laboratories
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Labor Dr. Merk & Kollegen
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Poolbeg Pharma
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Incyte
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genmab
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biogen
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦